Transaction
|
December 14, 2021

Synthetic Biologics to acquire VCN Biosciences for over $4M in upfront cash

VIEW ORIGINAL PRESS RELEASE
Latest News
Transaction
Unit Of Li Ka-Shing’s CK Life Sciences To Merge With Nasdaq-Listed Biotech Company In $100 Million Deal
TRANSACTION
Virios Therapeutics Acquires Wex Pharmaceuticals for $100 Million to form Dogwood Therapeutics and Concurrently Completes a $19.5 Million Financing
TRANSACTION
Onconetix Completes Up to $27 Million Equity Financing
Transaction
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Transaction
MolecuLight Secures $11.7 Million in Financing to Accelerate Global Expansion
BACK TO NEWS
Have a lightbulb moment with us
Sign up for updates from Tungsten
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Tungsten Partners LLC d/b/a Tungsten Advisors is not a registered broker-dealer, and Finalis Securities LLC and Tungsten Partners LLC d/b/a Tungsten Advisors are separate, unaffiliated entities.

www.tungstenadv.com is operated by Tungsten Partners LLC, a privately held Delaware Limited Liability Company. Tungsten Partners LLC provides strategic advisory services.

Business Continuity Plan  |  Privacy Policy  |  FINRA Broker Check

CONTACT:
INFO@tungstenadv.com
CONNECT:
LINKED IN
ADDRESS:
767 Third Ave, 29th Floor
New York, NY 10017
CONTACT:
INFO@tungstenadv.com
CONNECT:
LINKED IN
ADDRESS:
767 Third Ave, 29th Floor
New York, NY 10017

Securities are offered through Finalis Securities LLC Member FINRA/SIPC. Tungsten Partners LLC d/b/a Tungsten Advisors and Finalis Securities LLC are separate, unaffiliated entities.

www.tungstenadv.com is operated by Tungsten Partners LLC, a privately held Delaware Limited Liability Company. Tungsten Partners LLC provides strategic advisory services.

Business Continuity Plan  |  Privacy Policy  |  FINRA Broker Check